ISCNF - Isracann Biosciences Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0298
0.0000 (0.00%)
At close: 03:57PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.0298
Open0.0298
BidN/A x N/A
AskN/A x N/A
Day's Range0.0250 - 0.0298
52 Week Range0.0090 - 0.0620
Volume67,146
Avg. Volume198,185
Market Cap5.245M
Beta (5Y Monthly)0.04
PE Ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings DateApr 27, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ISCNF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CNW Group

    IIROC Trading Halt - IPOT

    The following issues have been halted by IIROC:

  • GlobeNewswire

    Isracann Biosciences Provides Bi-Weekly Default Status Report

    VANCOUVER, British Columbia, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that further to its news release dated September 29, 2022 (the “Default Announcement”), the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) on September 29, 2022, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”). Pursuant to the M

  • GlobeNewswire

    Isracann Biosciences Announces Delay in Filing Annual Financial Statements

    VANCOUVER, British Columbia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that the filing of its audited annual financial statements for the year ended May 31, 2022, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the “Annual Financial Filings”) were not filed by the required filing deadline of September 28, 2022 (the “Filing Deadline”). The Annual Financial F

  • GlobeNewswire

    Isracann Bioscience Facilitated Genetics Arrive in Israel

    Partner Facility Now Growing Canadian Cannabis StrainsVANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce that previously shipped genetics have cleared Israeli customs and are being raised as mother stock. “The Israeli market will now have access to premium Canad

  • GlobeNewswire

    Isracann Bioscience Facilitates Cannabis Genetics Shipment to Israel

    VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”), a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor, is pleased to announce it has facilitated its first shipment of cannabis strains to Israel. The agreement for genetics is directly between United Greeneries Ltd, a licensed Canadian producer of high calibre craft cannabis, and Intel

  • GlobeNewswire

    Praesidio signs distribution agreement with Pure Integrative Pharmacy

    VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce that it has signed a distribution agreement for Praesidio Health (Praesidio) products with Pure Integrative Pharmacy (PURE). “I am excited to announce our first executed distribution agreement in Canada”, says

  • GlobeNewswire

    Isracann Adds Super Bowl MVP and Mental Health Advocate Mark Rypien to Advisory Board

    VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division (Praesidio Health) in Canada and holdings in Israel, is please to announce the appointment of Super Bowl XXVI MVP and mental health advocate Mr. Mark Rypien to its advisory board. CEO Phil Floucault notes, “Mr. Rypien had a distinguished 13-year career in the NFL during which he was na

  • GlobeNewswire

    Isracann Biosciences Announces Closing of First Tranche of $0.05 Unit Private Placement

    VANCOUVER, British Columbia, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that it has closed the first tranche of its previously announced non-brokered private placement. The Company issued 4,679,600 units (the “Units”) at a price of $0.05 per Unit for aggregate gross proceeds of $233,980 (the “Offering”). Each Unit consists of one common share of the Company (a “Share”) and one common share purchase wa